Last reviewed · How we verify
Home Based Daratumumab Administration for Patients With Multiple Myeloma
This clinical trial tests the treatment effect of home based daratumumab administration in treating patients with multiple myeloma. Darzalex Faspro is a combination of two drugs (daratumumab and hyaluronidase) used to treat adults with multiple myeloma. Daratumumab is in a class of medications called monoclonal antibodies. It works by helping the body to slow or stop the growth of cancer cells. Hyaluronidase-fihj is an endoglycosidase. It helps to keep daratumumab in the body longer so that the medication will have a greater effect. Standard medical care requires Darzalex-Faspro treatment be administered during visits to the cancer center. Receiving medication in the home setting, may decrease cost and burden of care in patients with multiple myeloma.
Details
| Lead sponsor | Thomas Jefferson University |
|---|---|
| Phase | PHASE4 |
| Status | COMPLETED |
| Enrolment | 20 |
| Start date | Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed May 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Plasma Cell Myeloma
Interventions
- Daratumumab and Hyaluronidase-fihj
- Questionnaire Administration
- Quality-of-Life Assessment
- Interview
Countries
United States